AstraZeneca Presents Results of Imfinzi in P-III (HIMALAYA) and (TOPAZ-1) Trial for Liver and Biliary Tract Cancer at EASL 2022 and ESMO World GI 2022
Shots:
- The P-III (HIMALAYA) trial evaluates Imfinzi (1500mg, q4w) + tremelimumab (300mg) vs sorafenib in 1324 patients with HCC regardless of baseline liver functional reserve. The P-III (TOPAZ-1) trial evaluates Imfinzi + CT vs PBO + CT in 685 patients with unresectable advanced or m-BTC irrespective of primary tumor location
- The exploratory subgroup analysis showed consistent OS benefits in both trials. In (HIMALAYA) trial, ORR, DoR & tolerability profiles for STRIDE were consistent regardless of ALBI score & liver function was stable over time & the outcomes illustrate the effects of treatment discontinuation & QoL benefits for maintaining patients on treatment with the STRIDE regimen
- In (TOPAZ-1) trial, the incidence of grade 3 or 4 AEs & TRAEs were comparable b/w treatment groups
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
